Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

ADHD Clinical Trial

Official title:

A Phase 3b, Randomized, Double-blind, Multicenter, Placebo Controlled, Dose Optimization, Crossover, Analog Classroom, Safety and Efficacy Study of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD))

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01274221
• Other study ID #: SPD489-321
• Status: Withdrawn
• Phase: Phase 3
• Start date: March 6, 2011
• Est. completion date: May 4, 2011

Study information

• Verified date: May 2021
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of the study is to evaluate the efficacy of SPD489 compared to placebo in adolescent subjects (13-17 years of age inclusive) with ADHD in the analog classroom setting based on the Permanent Product Measure of Performance (PERMP) total score assessed across 2, 4, 9, 13, 14, and 15 hours post-dose on the last day of each double-blind crossover period.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 4, 2011
• Est. primary completion date: May 4, 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 13 Years to 17 Years

Eligibility

Inclusion Criteria:

1. Subject must be male or female, 13-17 years of age inclusive, at the time of consent.

2. The parent/LAR must be available at approximately 7:00 AM (±2 hours) to dispense the dose of investigational product for the study duration.

3. Subject, who is a female, must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test and a negative urine pregnancy test and agree to comply with any applicable contraceptive requirements of the protocol.

4. Subject meets the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR) criteria for a primary diagnosis of ADHD based on a detailed psychiatric evaluation.

5. Subject has an Attention Deficit/Hyperactivity Disorder Rating Scale-Fourth Edition (ADHD-RS-IV) total score =28.

6. Subject is functioning at an age-appropriate level intellectually.

7. Subject is able to swallow a capsule.

Exclusion Criteria:

1. Subject has a current, controlled (with medications prohibited in this study) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as any significant comorbid Axis II disorder or significant Axis I disorder (such as post traumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, depressive or anxiety disorder) or other symptomatic manifestations that, in the opinion of the examining clinician, will contraindicate treatment with SPD489 or confound efficacy or safety assessments.

2. Subject has a documented history of aggressive behavior serious enough to preclude participation in regular classroom activities, as determined by the Investigator. Oppositional defiant disorder is not exclusionary.

3. Subject is currently considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or has a prior history of, or is currently, demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded based on the assessment of the Investigator

4. Subject is underweight.

5. Subject is significantly overweight.

6. Subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or an infectious process requiring antibiotics), disability, or other condition that might confound the results of safety assessments conducted in the study or that might increase risk to the subject.

7. Subject has a history of seizures (other than infantile febrile seizures), a chronic or current tic disorder, a current diagnosis, and/or a known family history of Tourette's Disorder. Subject has a history of tics that are judged by the Investigator to be exclusionary.

8. Subject has a known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may place him/her at increased vulnerability to the sympathomimetic effects of a stimulant drug.

9. Subject has a known family history of sudden cardiac death or ventricular arrhythmia.

10. Subject has any clinically significant electrocardiogram (ECG) or clinically significant laboratory abnormality.

11. Subject has current abnormal thyroid function. Treatment with a stable dose of thyroid medication for at least 3 months is permitted.

12. Subject has a documented allergy, hypersensitivity, or intolerance to amphetamine or to any excipients in the investigational product.

13. Subject has failed to respond to 1 or more adequate courses (dose and duration) of amphetamine therapy.

14. Subject has a history of suspected substance abuse or dependence disorder (excluding nicotine) in accordance with DSM-IV-TR criteria.

15. Subject has a positive urine drug result (with the exception of subject's current stimulant therapy, if any).

16. Subject has taken another investigational product or has taken part in a clinical study within 30 days prior to the Screening visit.

17. Subject has previously been screened for this study or has participated in any other SPD489/NRP104 clinical studies.

18. Subject has glaucoma.

19. Subject is taking other medications that have central nervous system (CNS) effects or affect performance, such as sedating antihistamines and decongestant sympathomimetics, or are monoamine oxidase inhibitors. Stable use of bronchodilator inhalers is not exclusionary.

20. Subject is female and is pregnant or lactating.

21. Subject is well controlled on his/her current ADHD medication with acceptable tolerability.

Related Conditions & MeSH terms

• ADHD
• Attention Deficit Disorder with Hyperactivity

Intervention

Drug:
• SPD489
1 capsule per day throughout the open-label treatment phase and for one week of the double-blind crossover phase

Other:
• Placebo
1 capsule per day for one week of the double-blind crossover phase

Locations

Country	Name	City	State
United States	Florida Clinical Research Center, LLC	Bradenton	Florida
United States	Bayou City Research, Ltd.	Houston	Texas
United States	Center for Psychiatry and Behavioral Medicine, Inc.	Las Vegas	Nevada
United States	Clinical Study Centers, LLC	Little Rock	Arkansas
United States	John M. Turnbow, MD, PA	Lubbock	Texas
United States	Vince and Associates Clinical Research, Inc.	Overland Park	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
Shire

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Permanent Product Measure of Performance (PERMP) Total Score		7 Days
Secondary	Attention Deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV) Total Score		7 Days
Secondary	Conners' Parent Rating Scale - Revised (CPRS-R) Total Score		7 Days
Secondary	Clinical Global Impressions - Global Improvement (CGI-I) Rating Scale Score		7 Days
Secondary	Vital Signs (includes oral or tympanic temperature, sitting blood pressure, pulse and respiratory rate) and Body Height and Weight		Baseline, Weeks 7, 14, 21, 28, 35 and 42
Secondary	Columbia-Suicide Severity Rating Scale (C-SSRS)		Baseline, Weeks 7, 14, 21, 28, 35 and 42